Prism BioLab
PRISM BioLab is a Japan-based biotech (TSE Growth: 206A) that develops orally available small-molecule drug candidates against protein-protein interaction targets using its proprietary PepMetics® peptidomimetic platform, licensing assets and the platform itself to global pharmaceutical partners such as Eisai, Eli Lilly, and Ono Pharmaceutical.
- Company typePublic
- Founded2006
- HeadquartersFujisawa, Japan
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Prism BioLab does
PRISM BioLab is a Japan-based biotechnology company founded in 2006 that develops orally available small-molecule drug candidates against protein-protein interaction (PPI) targets historically classified as "undruggable." The company's core asset is the PepMetics® Technology platform, a proprietary peptidomimetic chemistry system that synthesizes stable, conformationally-locked small molecules mimicking the α-helix and β-turn secondary structures of natural peptides. The platform is supported by three library tiers — a Real Library of 20,000+ synthesized compounds, an On-demand Library capable of producing up to 200,000 molecules from prepared intermediates, and a Virtual Library enabling in silico screening of up to 250 million formulations — together with proprietary analysis tools (PCD Plot, PMA Map), 40+ scaffold types and 50+ side chains, and a patent estate spanning 16 patent families (WO2009/148192 through WO2023/200017).
The company operates a pure B2B business model with no consumer-facing products, generating revenue exclusively through technology licensing, co-development collaborations, and milestone/royalty arrangements with pharmaceutical partners. Its two go-to-market motions are (i) advancing in-house programs to clinical candidates for out-licensing — most notably E7386, a β-catenin/CBP inhibitor co-developed with Eisai and currently in Phase 1 oncology trials — and (ii) "Platform Collaborations," which deploy the PepMetics platform against partner-specified targets. Commercial relationships include major pharma names such as Eisai, Eli Lilly, Ono Pharmaceutical, Ohara Pharmaceutical, Roche/Genentech, Merck KGaA, and Boehringer Ingelheim (the latter agreement having expired in 2025). PRISM completed its IPO on the Tokyo Stock Exchange Growth Market on July 2, 2024 (ticker 206A) and is headquartered in Fujisawa, Kanagawa, with a Tokyo office relocated in January 2026.
Prism BioLab firmographics
Firmographics- Name
- Prism BioLab
- Legal name
- 株式会社PRISM BioLab
- Website
- https://prismbiolab.com
- Company type
- Public
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- PRISM BioLab is a Japan-based biotech (TSE Growth: 206A) that develops orally available small-molecule drug candidates against protein-protein interaction targets using its proprietary PepMetics® peptidomimetic platform, licensing assets and the platform itself to global pharmaceutical partners such as Eisai, Eli Lilly, and Ono Pharmaceutical.
- Ownership category
- akta.pro rank
Prism BioLab industry classification
Industry- Product category
- Peptide Mimetic Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE)
Keywords
Where Prism BioLab is headquartered
LocationHeadquarters
- HQ city
- Fujisawa
- HQ country
- Japan
- HQ region
- Asia
Offices2 records
Markets served
Prism BioLab business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Others
Revenue model
- Licensing Revenue: PRISM licenses its technology and compounds to pharmaceutical partners. Revenue includes upfront payments, milestone payments upon achievement of research and development milestones, and potential royalties on future sales.
- Milestone Payments: The company receives milestone payments as collaborative research progresses through various stages. For example, achieved initial milestone and received payment from Ono Pharmaceutical in November 2025 for oncology drug discovery collaboration.
- Series C Funding: Raised ¥1.3 billion (approximately $9.3 million) in Series C funding on August 27, 2021, from investors including santec Holdings.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Prism BioLab product offering
Product offeringCore offering
PRISM BioLab is a biotechnology company that develops PepMetics® Technology, a proprietary drug discovery platform for creating peptide mimetic small molecules that mimic α-helix or β-turn peptides using unique, stable scaffolds. The company maintains a PepMetics® Real Library of more than 20,000 compounds and offers on-demand synthesis services, enabling partners to drug historically challenging protein-protein interaction targets and intrinsically disordered proteins.
Product overview
PRISM BioLab is a biotechnology company with a unified PepMetics® Technology platform centered on proprietary peptide mimetic small molecules that mimic α-helix and β-turn peptides. The platform comprises the core PepMetics® Technology (for synthesizing molecules that act like peptides but can be synthesized like small molecules), supported by three library tiers (Real Library with 20,000+ synthesized compounds, On-demand Library for rapid synthesis of up to 200K compounds, and Virtual Library for screening 250M+ formulations). Supporting technology modules include Sequence Mimetics, Structure-Based Drug Design, and IDP targeting. The company operates two business models: In-house Pipelines advancing programs to clinical candidates for licensing, and Platform Collaborations providing the platform to pharmaceutical partners. Key clinical candidates include E7386 (jointly developed with Eisai, Phase 1 for oncology) and FEP600/FEP633 (eIF4E/eIF4G1 inhibitors in lead optimization).
Differentiator
Problem solved
Functional benefit
Products and services
- PepMetics Technology
Quantifiable outcome
- E7386 Phase 1 clinical trial completed with results published in ESMO OPEN; cardiac safety data shared at ASCO Annual Meeting 2025
- +2 more outcomes
Companies that use Prism BioLab
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles1 record
Prism BioLab technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature5 records
Prism BioLab partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core, flagship and minor.
- Receptor.AI Inc.coreDrug discovery collaboration to develop an integrated AI-navigated, physics-guided platform for discovering orally available small molecules targeting protein-protein interactions, membrane proteins, and complex receptor systems. Combines PRISM's PepMetics chemistry with Receptor.AI's multi-objective AI navigation engine. Initial focus on metabolic diseases including obesity.
- Talus BiosciencecoreCollaboration to develop inhibitors targeting transcription factors (TF) and protein-protein interactions (PPI). Uses Talus Bio's assay technologies with PRISM's chemistry and small-molecule libraries to discover and optimize new drug candidates for challenging targets.
- Ono Pharmaceutical Co., Ltd.coreDrug discovery collaboration focused on oncology. Involves development of small molecule inhibitors targeting protein-protein interactions. Initial research milestone achieved with milestone payment received in November 2025.
- Eisai Co., Ltd.flagshipCo-development of E7386, a selective inhibitor of β-catenin/CBP interaction. Phase 1 clinical trial completed with results published in ESMO OPEN. Cardiac safety evaluation results shared at ASCO Annual Meeting 2025. Preclinical research results presented at AACR Annual Meeting 2026.
- Eli Lilly and CompanycoreLicense and research collaboration on a protein-protein interaction target. PRISM granted rights to Lilly for use of its technology on specific targets.
- Ohara Pharmaceutical Co., Ltd.coreLicense agreement for PRI-724 compound. Clinical milestone achieved in May 2023 as Ohara advanced OP-724 clinical trials. This represents a significant validation of PRISM's technology.
- Boehringer Ingelheim International GmbHminorResearch and license agreement for novel targets. The agreement has expired as announced in 2025.
- Roche / GenentechminorListed as partner on company partners page. Nature of collaboration not specified in detail in available sources.
- Merck KGaAminorListed as partner on company partners page. Nature of collaboration not specified in detail in available sources.
Scale indicators7 records
Recent moves8 records
Expansion highlights6 records
Prism BioLab competitors and assessment
Company assessmentDirect peers
- PeptiDream: Japanese peptide-based drug discovery platform company using non-standard peptide libraries to address challenging targets including PPIs. Direct comparison to PRISM given shared Japan base, peptide-focused platform approach, and pharma partnership model.
- Bicycle Therapeutics: Clinical-stage biotech developing bicyclic peptide therapeutics (bicycles) that combine attributes of small molecules and biologics to drug PPIs and oncology targets. Direct peer to PRISM in peptide-inspired therapeutic discovery targeting PPIs.
- Arvinas: Pioneer in targeted protein degradation (PROTACs) for PPIs and previously 'undruggable' targets, with pharma partnerships and clinical-stage oncology pipeline. Direct peer to PRISM in addressing PPIs with novel small-molecule modalities.
- Kymera Therapeutics: Clinical-stage biotech developing small-molecule protein degraders (Pegasus platform) targeting PPIs in immunology and oncology. Direct peer in the small-molecule PPI targeting space with major pharma partnerships.
- Morphic Therapeutic: Clinical-stage biotech developing oral small-molecule inhibitors of integrins and other PPIs using structure-based design. Direct peer to PRISM in structure-based small-molecule design against high-value PPIs.
- Foghorn Therapeutics: Clinical-stage biotech targeting chromatin regulatory complexes and PPIs in oncology. Comparable to PRISM in using novel chemistry platforms to drug challenging protein-protein interactions and transcription factor targets.
- HotSpot Therapeutics: Biotech developing allosteric small molecules targeting PPIs and protein functions through natural regulatory hotspots. Direct peer in targeting previously 'undruggable' PPIs with proprietary small-molecule chemistry.
- Aileron Therapeutics: Developer of stapled peptide therapeutics designed to stabilize alpha-helical structures and disrupt PPIs. Closely comparable technology approach to PRISM's peptide-mimetic scaffold strategy for PPI modulation.
- C4 Therapeutics: Clinical-stage degrader company developing small-molecule degraders (dTAGs) targeting disease-causing proteins. Direct peer in targeting PPIs and protein functions with novel small-molecule platforms and pharma partnerships.
Broad incumbents
- Eisai Co., Ltd. Major Japanese pharmaceutical company and PRISM's flagship partner for E7386 co-development. Broad incumbent that also operates its own internal PPI/small-molecule programs and competes for partnerships in oncology and neuroscience.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Prism BioLab social profiles
Digital presencePrism BioLab financial estimates
Financial estimateRevenue estimate
Valuation estimate
Prism BioLab leadership team
Management profileNumber of profiles
Profiles1 record
Prism BioLab funding detail
Funding detailFunding overview
Funding rounds5 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Prism BioLab M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Prism BioLab
What does Prism BioLab do?
PRISM BioLab is a biotechnology company that develops PepMetics® Technology, a proprietary drug discovery platform for creating peptide mimetic small molecules that mimic α-helix or β-turn peptides using unique, stable scaffolds. The company maintains a PepMetics® Real Library of more than 20,000 compounds and offers on-demand synthesis services, enabling partners to drug historically challenging protein-protein interaction targets and intrinsically disordered proteins.
Is Prism BioLab a public or private company?
Prism BioLab is a public company. It is classified as unknown and is currently operating.
When was Prism BioLab founded?
Prism BioLab was founded in 2006. It employs 11 to 50 people.
Where is Prism BioLab based?
Prism BioLab is headquartered in Fujisawa, Japan, in the Asia region.
How does Prism BioLab make money?
Three revenue lines are on record. Licensing Revenue is the primary driver. The others are milestone Payments and series C Funding.
Who are Prism BioLab's main competitors?
Direct peers on record are PeptiDream, Bicycle Therapeutics, Arvinas, Kymera Therapeutics, Morphic Therapeutic, Foghorn Therapeutics, HotSpot Therapeutics, Aileron Therapeutics and C4 Therapeutics. Eisai Co., Ltd. is listed as a broad incumbent.
Does Prism BioLab have an API?
No public API is recorded for Prism BioLab.
What industry is Prism BioLab in?
Prism BioLab's product category is Peptide Mimetic Drug Discovery Platform. Its primary akta.pro industry code is HLAGAHAE, Chiral / Asymmetric Synthesis & Complex Chemistry Services. Its NAICS code is 541714 and its SIC code is 8731.